WellFish Tech has announced a commercial partnership with Andfjord Salmon, the land-based producer operating at Kvalnes on the island of Andøya in northern Norway.
Under the agreement, WellFish Predict will generate quantitative data on the physiological condition of fish throughout the production cycle. The programme will provide Andfjord Salmon’s team with objective, internally sourced biological data to sit alongside existing environmental and operational monitoring, offering granular health intelligence to inform production decisions.
The predictive models cover mortality risk at 14 and 28 days and gill health up to six weeks ahead of visible pathology. These capabilities are particularly relevant in RAS and flow-through environments where early biological signals carry significant operational value.
Andfjord Salmon operates a land-based flow-through system drawing deep Arctic seawater at Kvalnes and has reported survival rates consistently above 99 percent since entering production. As the company scales toward its licensed capacity, establishing a robust health monitoring baseline is increasingly important for production management and for the evidential record underpinning welfare commitments.
“We have always believed that good outcomes for fish health are inseparable from good outcomes for the business,” said Martin Rasmussen, CEO of Andfjord Salmon. “Blood biochemistry gives us a direct window into the physiological state of our fish that no environmental sensor or behavioural observation can provide. We want the decisions we make at Kvalnes to be grounded in the most precise and robust data available.”
Charlie Granfelt, CEO of WellFish Tech, added: “Andfjord Salmon have built something genuinely exceptional at Kvalnes, and they are asking exactly the right question – not just how do we maintain these results, but how do we understand them well enough to be certain we can sustain them at scale.”
